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Combined magnetic resonance imaging and magnetic resonance
spectroscopy imaging in the diagnosis of prostate cancer: a
systematic review and meta-analysis
Abstract
CONTEXT: Magnetic resonance imaging (MRI) combined with magnetic resonance spectroscopy
imaging (MRSI) emerged as a promising test in the diagnosis of prostate cancer and showed
encouraging results. OBJECTIVE: The aim of this systematic review is to meta-analyse the diagnostic
accuracy of combined MRI/MRSI in prostate cancer and to explore risk profiles with highest benefit.
EVIDENCE ACQUISITION: The authors searched the MEDLINE and EMBASE databases and the
Cochrane Library, and the authors screened reference lists and contacted experts. There were no
language restrictions. The last search was performed in August 2008. EVIDENCE SYNTHESIS: We
identified 31 test-accuracy studies (1765 patients); 16 studies (17 populations) with a total of 581
patients were suitable for meta-analysis. Nine combined MRI/MRSI studies (10 populations) examining
men with pathologically confirmed prostate cancer (297 patients; 1518 specimens) had a pooled
sensitivity and specificity on prostate subpart level of 68% (95% CI, 56-78%) and 85% (95% CI,
78-90%), respectively. Compared with patients at high risk for clinically relevant cancer (six studies),
sensitivity was lower in low-risk patients (four studies) (58% [46-69%] vs 74% [58-85%]; p>0.05) but
higher for specificity (91% [86-94%] vs 78% [70-84%]; p<0.01). Seven studies examining patients with
suspected prostate cancer at combined MRI/MRSI (284 patients) had an overall pooled sensitivity and
specificity on patients level of 82% (59-94%) and 88% (80-95%). In the low-risk group (five studies)
these values were 75% (39-93%) and 91% (77-97%), respectively. CONCLUSIONS: A limited number
of small studies suggest that MRI combined with MRSI could be a rule-in test for low-risk patients. This
finding needs further confirmation in larger studies and cost-effectiveness needs to be established.
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Abstract 
Context: Magnetic resonance imaging (MRI) combined with magnetic resonance 
spectroscopy imaging (MRSI) emerged as a promising test in the diagnosis of prostate cancer 
and showed encouraging results. 
Objective: The aim of this systematic review is to meta-analyse the diagnostic accuracy of 
combined MRI/MRSI in prostate cancer and to explore risk profiles with highest benefit. 
Evidence Acquisitions: The authors searched the MEDLINE, EMBASE and the Cochrane 
Library and screened reference lists and contacted experts. There were no language 
restrictions. Last search was performed in August 2008. 
Evidence Synthesis: We identified thirty-one test accuracy studies (1’765 patients); sixteen 
studies (17 populations) with a total of 581 patients were suitable for meta-analysis. Nine 
combined MRI/MRSI studies (10 populations) examining men with pathologically confirmed 
prostate cancer (297 patients; 1518 specimens) had a pooled sensitivity and specificity on 
prostate subpart level of 68% (95% CI; 56% to 78%) and 85% (78% to 90%). Compared to 
patients with a high risk for clinically relevant cancer (six studies) sensitivity was lower in 
low risk patients (four studies) (58% (46% to 69%) vs. 74% (58% to 85%); p>0.05) but 
higher for specificity (91% (86% to 94%) vs. 78% (70% to 84%); p<0.01)). Seven studies 
examining patients with suspected prostate cancer at combined MRI/MRSI (284 patients) had 
an overall pooled sensitivity and specificity on patients level of 82% (59% to 94%) and 88% 
(80% to 95%). In the low risk group (five studies) these values were 75% (39% to 93%) and 
91% (77% to 97%) respectively. 
Conclusions: A limited number of small studies suggest that magnetic resonance imaging 
combined with magnetic resonance spectroscopy could be a rule-in test for low risk patients. 
This finding needs further confirmation in larger studies and cost-effectiveness needs to be 
established.
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Introduction 
In 2007 the American Cancer Society indicated that prostate cancer is the most commonly 
diagnosed cancer in the US and with an estimated 27’050 prostate cancer related deaths, the 
second leading cause of cancer related fatality [1]. This is described in a more meaningful 
way by Walsh [2], who wrote that approximately one out of six men in the USA received a 
diagnosis of prostate cancer in his lifetime, and one out of 34 died from it. Current statistics 
show that prostate cancer incidence rates are decreasing since 1992 after reaching a peak in 
the mid 90ties due to the implementation of the PSA screening in the late 80ties. [3] Whether 
this is a sustained decrease is questionable. Data on demographic changes clearly show that 
the population of the developed world is ageing rapidly. For example Yancik and colleagues 
predicted a doubling of the population at the age of 65 years or older by the year 2030 in the 
USA [4]. Since almost two third of new prostate cancer cases occur in the elderly it can be 
expected that prostate cancer incidence will rise again. British researchers predict that cancers 
of the prostate gland could overtake lung cancer as the most common form of the disease in 
Britain within 20 years. [5] 
 
Arguably the continuing increase in prostate cancer detection may be attributable to 
increased screening through prostate-specific antigen (PSA) testing. However, both in 
screening and diagnostic work-up PSA appear to be of low accuracy: using a threshold of 
<4ng/ml showed a prevalence of only 15% of prostate cancer [6] and a threshold between 4 
and 10ng/ml a prevalence of only 33% of prostate cancer [7].Moreover, rule-in diagnosis with 
transrectal needle biopsy has been shown to be remarkably inaccurate [8-10] with a cancer 
missing rate of up to 20% using a traditional sextant biopsy schema; indeed, an approach with 
a ten to twelve prostate needle biopsy schema leads to a 30% improvement in cancer detecting 
[11]. Over the last decade, imaging technologies, such as combined magnetic resonance 
imaging (MRI) and magnetic resonance spectroscopy imaging (MRSI) have shown promise 
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for improving the detection and characterization of prostate cancer. However, these 
technologies have not yet entered into routine clinical care and their clinical role remains 
debated.  
 
The aim of this systematic review and meta-analysis was to establish the current role 
of combined MRI and MRSI in the diagnosis of prostate cancer and to explore risk profiles 
with the highest benefit. 
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Evidence Acquisition 
We used methods recommended by the Cochrane methods group for the systematic review of 
screening and diagnostic tests [12]. 
Identification of studies 
We searched MEDLINE, Cochrane Library and EMBASE to identify diagnostic 
studies evaluating the accuracy of combined MRI and MRSI in the diagnosis of prostate 
cancer. Last search was performed in August 2008. Checking the reference lists of included 
studies and contacting experts in the field complemented electronic searches. The detailed 
search strategy for Medline can be found in the Appendix. 
Study selection 
 We included studies if they compared MRI in combination with MRSI results and 
potentially other imaging methods (e.g. diffusion and contrast enhanced MRI) with the results 
of prostate biopsies or prostatectomy specimens in patients with either previously diagnosed 
or suspected prostate cancer. The minimum requirement for inclusion was enough 
information to fill the two-by-two table. All papers considered potentially eligible by one of 
the two observers were ordered and a checklist was used to determine final eligibility. 
Disagreements about inclusion or exclusion were resolved by consensus. 
 We initially included thirty-one studies [8,13-42]. For details see figure 1. For the 
meta-analysis we excluded six studies (two with additional diffusion weighted MRI [23,28], 
one with additional diffusion weighted and contrast enhanced MRI [30] and three others 
without use of an endorectal coil [24,32,39]) involving a standard MRI/MRSI protocol 
defined as MRI using an endorectal coil and combined with MRSI on a 1.5 Tesla MR 
scanner. For technical details of imaging methods see Table 1. We also excluded seven 
studies using MRI just as an anatomical reference for MRSI-interpretation 
[17,18,26,27,36,41,42] without using the morphological information from MRI in the 
interpretation..For selection details see Figure 2.  
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We grouped the remaining eighteen studies first into reports based on cancer status 
(proven cancer versus suspected cancer) at the time of imaging and secondly into reports 
based on degree of pathologic correlation (cancer anywhere in the prostate versus a more 
exact pathologic correlation i.e., hemi-prostate, sextant etc.). Typically, studies including men 
with proven cancer were those studying a part of prostate as single pathologic correlative and 
studies including men with suspected cancer were those using the whole prostate as single 
pathologic correlative. All but two studies followed this pattern [16,31]. For meta-analysis we 
excluded two further studies; the study of Shukla-Dave and colleagues [31] because they 
compared significant versus insignificant cancer instead of cancer versus non cancer and the 
study of Costouros and colleagues [16] because it focused on developing a MRSI scoring 
system and did not measure accuracy of cancer detection (Figure 2). Therefore, the final 
meta-analysis contained seven reports on men with suspected prostate cancer [8,13-
15,37,38,40] and ten populations (nine studies) analyzing correlations of parts of the prostate 
within men with proven cancer [19-22,25,29,33-35]. The study by Kaji and colleagues [22] 
contained two separate populations (with and without previous hormone treatment). We 
treated them as two separate studies. We excluded three further studies [43-45] because they 
used a diagnostic case-control design which is prone to show over optimistic accuracy 
measures [46] 
 
Data extraction and assessment of methodological quality 
The methodological quality of all eligible papers was assessed based on published 
recommendations [46]. Quality assessment involved scrutinizing the methods of data 
collection and patient selection, and descriptions of the test and reference standard. Studies 
were considered to be prospective if the study protocol preceded data collection. Blinding was 
fulfilled if the person making the definite imaging diagnosis did not know the results of the 
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pathologic examination. One reviewer assessed papers and extracted data using a standardized 
form (the data extraction form is available on request). This reviewer contacted a second 
reviewer if an item could not be clearly addressed. Decisions were based on a consensus 
between the two reviewers. Papers published in languages other than English, German or 
French were translated. 
 
Risk stratification 
We a priori defined a set of five parameters (men’s age, PSA, Gleason-score, number 
of previous negative prostate biopsies and rate or dimension of detected cancer) to classify 
study populations into low or high risk groups for clinically relevant prostate cancer. For 
example, we classified patients into the low risk group if PSA values were low (<10 ng/ml) or 
if previous needle biopsies had been negative. We classified men older than 65 years 
presenting with a Gleason Score higher than six and larger tumours (diameter > 5mm) as 
determined in the prostatectomy specimen or a high positive core rate (>10%) as high risk. 
The classification was performed separately by two urologists and discrepancies - often due to 
missing data especially concerning tumour dimensions or positive core rate - were discussed 
and resolved by consensus. 
 
Index test 
For each study we extracted details about the MR scanner field strength, use of an 
endorectal or superficial body coil, spectroscopic acquisition parameters and metabolic cut-off 
values for a positive result. In three studies that assessed different cut off values we chose the 
highest available (> 3 SD higher than normal) to optimize the false positive rate. If studies 
contained test performance results for experienced and inexperienced spectroscopy readers 
separately, we only used the data of the experienced examiners. Two urologists separately 
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classified the patient cohorts based on the studies’ inclusion criteria. Discrepancies were 
discussed and resolved by consensus.  
 
Sensitivity, specificity and accuracy calculation 
We calculated the sensitivity and specificity of the combined positive or negative 
MRI/MRSI result on patient level within the seven studies including patients with cancer 
suspicion. In the remaining nine studies (including ten populations) we calculated sensitivity, 
specificity of the combined positive or negative MRI/MRSI result not on patient level but on a 
prostate subpart level. Different to studies assessing test performance on patient level these 
studies match the cancer status (present/absent) of a prostate subpart with the test result 
(positive/negative) of that corresponding part of prostate.  
 
Statistical analysis 
For each study, we constructed a two-by-two contingency table consisting of true-
positive (TP), false-positive (FP), false-negative (FN), and true-negative (TN) results. For 
analysis, we called a result a true positive if both MRI and MRSI were concordant and were 
in agreement with the pathological findings. We calculated sensitivity as TP/(TP + FN) and 
specificity as TN/(FP + TN). We plotted results from individual studies in ROC space and 
estimated summary ROC curves using a unified model for meta-analysis of diagnostic test 
accuracy studies [47]. We also indicated on the ROC-figures the confidence and prediction 
regions. The advantage of doing this is that it provides estimates of average sensitivity and 
specificity across studies, and can be used to provide a 95 percent confidence region for this 
summary point and prediction regions within which we expect the sensitivity and specificity 
of 95 percent of future studies to lie. We performed stratified analyses for studies reporting on 
cancer status in terms of proven and suspected cancer at the time of the MRI/MRSI exam. In 
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these subgroups we also assessed differences in sensitivity and specificity between low and 
high risk patients in respect to clinically relevant cancer. We pooled results if at least four 
studies per stratum were available. Following recent recommendations we refrained from 
pooling positive and negative likelihood ratios because these are sensible parameters to 
analyze statistically in a meta-analysis. [48] Instead, we calculated the likelihood ratios from 
the estimated pooled sensitivities and specificities. All analyses were done using the Stata 
statistical software package (Version 9.2, College Station, Texas, USA). 
 
 10
Evidence Synthesis 
Identification of studies and study quality 
Figure 1 summarizes the process of identifying and selecting studies. Thirty-one 
studies met our primary inclusion criteria. Study characteristics are shown in Table 1.  
 
Study Quality 
Twelve out of thirty-one reports had a prospective design [8,15,17-
19,24,26,28,32,37,38,40]and ten studies had a retrospective design 
[14,16,21,22,29,31,34,39,42,49]. The remaining nine studies did not report details of data 
collection [20,23,25,30,33,35,36,41,50]. Ten studies had consecutive patient enrolment [8,17-
19,29,32,37,38,40,42] and two studies had a case-control design [23,30] comparing test 
performance among healthy subjects and men with suspected [23] and diagnosed [30] prostate 
cancer. Seven studies reported that the radiologist was unaware of histological findings 
[14,16,17,31,37,39,49]. In one study the most experienced radiologist had two years of 
experience in reading spectroscopic data [50] and in two other studies three years [18,34]. In 
ten studies the most experienced radiologist had at least four years of experience 
[14,16,17,21,25,28,31,39,42,49]. Ten studies did not specify years of experience but 
described radiologists as experienced or dedicated [8,19,24,26,32,35-38]. Eight studies did 
not report on the radiologists’ level of experience [15,20,22,23,29,30,33,41]. Seven studies 
reported the exclusion of patients after the imaging exam due to poor imaging quality 
[14,21,26,29,35,36,49].The number of excluded patients varied substantially ranging from 2 
percent [35] up to 41 percent [21]. The mean percentage of excluded patients within these 
seven studies was 17. Ten studies reported the exclusion of prostate subparts after imaging 
due to poor imaging quality [17,18,21,25,28,29,33-35,42]. The number of excluded prostate 
subparts varied substantially from 2 percent [33] up to 73 percent [21]. The median 
percentage of excluded prostate subparts in these nine studies was 17 percent. All studies 
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identified the presence of prostate cancer based on a histological analysis of tissue. In eleven 
studies [17,18,21,25,29,31,33-35,41,42] the tissue was obtained at prostatectomy, seventeen 
studies used tissue obtained at prostate needle biopsy [8,15,16,20,22-24,26,28,32,36-
40,49,50] and two studies used both tissue from prostatectomy if available or from needle 
biopsy [14,30]. One study relied on routine histological reports if structured histological 
assessments had not been performed within the study [19]. For details see Table 1. 
 
Characteristics of the study population 
Study populations and settings were heterogeneous (Table 1). The mean age of 
participants ranged from 56 to 72.6 years, mean PSA ranged from 5.9 (one median = 5.4, 
Shukla-Dave) to 66.4 ng / ml and mean Gleason-scores ranged from 5.3 to 7. Insufficient 
description of these variables - age, PSA and Gleason score - was found in Fifteen studies 
[13,14,22,24-26,30-32,34-37,41,50]. Sixteen studies enrolled patients with previously 
diagnosed prostate cancer [17-22,25,28-31,33-35,41,42]. For imaging interpretation, these 
studies used the prostatectomy specimen as the standard of reference with correlation to a 
specific region of the prostate. Fifteen studies enrolled patients with suspected prostate cancer 
[8,14-16,23,24,26,32,36-40,49,50], seven of them involved patients with a prior negative 
biopsy [8,16,26,37,38,40,50]. For imaging interpretation, these studies used the biopsy as the 
standard of reference without correlation to a specific region of the prostate. For details see 
Table 1. 
 
Pooled sensitivity and specificity 
Confirmed versus suspected prostate cancer at the time of imaging 
Table 2 shows for each study population the number of true positives, false positives, false 
negatives and true negatives, as well as sensitivity and specificity. The accuracy parameters in 
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studies assessing patients with suspected cancer are based on patient level and in studies 
assessing patients with previously diagnosed cancer on classification of prostate subpart level. 
The pooled mean sensitivity of ten two-by-two tables investigating men with confirmed 
cancer using a cancer threshold value for MRSI of > 3 SD deviations from normal (Choline + 
Creatinine)/Citrate, was 68% (95% CI; 56% to 78%) and specificity was 85% (95% CI; 78% 
to 90%). (Figure 3) The corresponding positive and negative likelihood ratios were 4.5 and 
0.37. The pooled sensitivity and specificity of five studies investigating men with suspected 
prostate cancer was 82% (95% CI; 59% to 94%) and 88% (95% CI; 80% to 95%). (Figure 4) 
The corresponding positive and negative likelihood ratios were 6.8 and 0.15. 
 
Risk stratification in the confirmed cancer group 
For the confirmed prostate cancer studies we performed a risk-stratification for patient cohorts 
with low and high pretest probability of having clinical relevant cancer. Low risk patients had 
lower sensitivity [19,21,29,33] (58% (46% to 69%) vs. 74% (58% to 85%); p>0.05) but 
higher specificity (91% (86% to 94%) vs. 78% (70% to 84%); p<0.01)) than high risk patients 
[20,22,25,34,35] for prostate cancer detection (Figures 5 and 6).  
 
Risk stratification in the suspected cancer group 
We were unable to calculate pooled estimates for the high risk group. In the low risk group 
[8,15,37,38,40] sensitivity was 75% (39% to 93%) and specificity was 91% (77% to 97%) 
respectively. (Figure 7) 
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Discussion 
 
This is the first meta-analysis examining the combined diagnostic value of Magnetic 
resonance imaging (MRI) and magnetic resonance spectroscopy imaging (MRSI) in the work-
up of prostate cancer patients. We found limited evidence indicating a potential role of this 
technique in the future. At this stage clinical implications of our results remain limited due to 
several reasons. Studies tended to be of limited size, applied different methods and 
investigated a broad spectrum of patients. Moreover, study quality and reporting was limited. 
For example, only seven studies reported that radiologists were blinded for pathological 
information and only few gave a detailed description of clinically relevant information of 
enrolled patients such as PSA levels and Gleason Scores. Finally, we found substantial 
variation in the way spectroscopy findings were used for the identification of prostate cancer 
indicating a lack of consensus regarding diagnostic criteria and thresholds.  
 
Our findings in context of existing literature 
We found two systematic [51,52] and two non-systematic reviews [53,54]. In 2002 
Engelbrecht and colleagues [52] made a first systematic attempt to summarize the clinical 
value of the MRI in local staging of prostate cancer. The study also assessed the value of 
MRSI in that field but failed to perform a meta-analysis due to the limited number of 
available studies. Their search was limited to the year 2000 and they only searched two 
databases. Moreover, all but three studies assessing the diagnostic value of MRSI in 
combination with MRI were published after the year 2000. The other meta-analysis 
investigated the diagnostic value of MR spectroscopy in the diagnosis of prostate cancer [51] 
but not the value of combined MRI/MRSI.  
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Strength and limitations 
Our review was based on thorough literature searches and careful data extraction, and 
included assessments of the methodological quality of diagnostic test accuracy studies. This is 
the first study performing a meta-analysis in this diagnostic field. We modelled sensitivity and 
specificity simultaneously applying a novel and valid meta-analytic method, which 
incorporates both within and between study variance [47]. In addition we performed stratified 
analyses to examine variability of results between subgroups of patients. Reporting of salient 
clinical features was suboptimal in some of the studies. This could have introduced bias in our 
results. A further limitation is that many studies used prostate needle biopsy cores as the 
reference method which is considered to be a poor gold standard due to the high missing rate. 
Moreover nine studies matched the cancer status (present/absent) of a prostate subpart with 
the test result (positive/negative) of that corresponding part of prostate to calculate sensitivity 
and specificity assuming that these figures represent a fair proxy for test performance in 
clinical practice. Also, due to the fact that some studies excluded substantial numbers of 
patients or prostate subparts due to poor imaging quality we cannot fully rule-out selection 
bias in these studies. Although we aimed at quantifying the additional value of combined MRI 
/ MRSI over MRI technology alone the paucity of such data in our set of studies impeded us 
from doing a solid analysis. Finally, we performed this systematic review in a rapidly 
evolving field of research and we cannot exclude that relevant reports appeared while 
completing this study.  
 
Implication for research  
We believe that future studies of the diagnostic value of new MR imaging technologies 
should include recent methodological recommendations for studies evaluating diagnostic tests 
[55]. Researchers should be encouraged to agree on data acquisition protocols and data 
analysis algorithms to increase the comparability of studies. Careful reporting of those 
 
 15
methods will facilitate the evaluation to the extent that the results are applicable to other 
clinical settings. For example, in the studies included in this meta-analysis the pathologic 
standard of reference for cancer presence varied substantially leading to variability in test 
performance measures [46].  
 
Implications for practice 
Based on the results of our study we think that it is too early to call for broad application of 
this method in clinical practice. We speculate that further improvement of the technology will 
increase its role in the future. For example higher field strengths will lead to a better spatial 
resolution and the combination of existing techniques with diffusion weighted imaging and 
dynamic contrast enhanced MRI could provide additional functional information concerning 
the presence and stage of prostate cancer. A further challenge needing resolution relates to the 
clinical circumstances for which MRI/MRSI is most useful. Can MRI/MRSI play a role in 
identifying cancer in men with a rising PSA but negative prior biopsies or can it help 
confirming that a biopsy procedure has not missed a clinically significant tumour? 
 
Conclusion 
A limited number of small studies suggest that magnetic resonance imaging combined with 
magnetic resonance spectroscopy could be a rule-in test for low risk patients. This finding 
needs further confirmation in larger studies and. cost-effectiveness needs to be established.  
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Figure 1: study flow 
Total of articles identified by primary search in electronic databases
(PubMed 269 , Cochrane Central 5, Embase 161, other 1; 84 duplicates)
Articles about diagnostic accuracy of MRSI in the diagnosis of prostate cancer
Articles definitive included in systematic review
Studies excluded after screening titles and abstracts 
Articles excluded
- lack of data to construct 2x2 table n = 23
- lack of involvement of MRSI n = 6
- not diagnostic approach (T2 vs T3) n = 3
- case-control design on subpart of 
prostate level n = 3
Studies excluded due to lack of original data
(reviews, comments)
Articles reporting the results of diagnostic studies (trials)
n = 352
n = 196
n = 156
n = 90
n = 35
n = 66
n= 31
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Figure 2: final study selection 
 
 
31 articles
(primary included)
Exclusion: no standard imaging procedure; n = 6
- Additional diffusion weighted MRI:   n = 2
- Additional diffusion weighted and 
contrast enhanced MRI: n = 1
- No endorectal coil: n = 3
25 articles
(standard imaging procedure)
Exclusion: no combined MRI/MRSI analysis; n = 7
MRI just as background for MRSI
18 articles
(combined analysis of MRI and MRSI findings)
Cancer status: diagnosed
n = 10
Cancer status: suspected
n = 8
Single pathologic correlative:
whole prostate
n = 7
Single pathologic correlative:
part of prostate
n = 1
Single pathologic correlative:
whole prostate
n = 1
Single pathologic correlative:
part of prostate
n = 9
Definitive analysis Definitive analysisExclusion; n = 2
Due to heterogeneity within
the group
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Figure 3: diagnosed prostate cancer – single pathologic correlative: part of prostate (cut off 
value MRSI > 3SD) 
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Figure 4: suspected prostate cancer – single pathologic correlative: whole prostate (cut off 
value MRSI > 3SD) 
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Figure 5: risk stratification within the group with diagnosed cancer / part of prostate - high 
risk of clinical relevant cancer 
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Figure 6: risk stratification within the group with diagnosed cancer / part of prostate – low 
risk of clinical relevant cancer 
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Figure 7: risk stratification within the group with the group with suspected cancer / whole 
prostate – low risk of clinical relevant cancer 
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Table 1 patient characteristics 
 
 
 
Author Year 
Number 
of 
patients 
mean age age range 
mean PSA 
(ng/ml) PSA range 
Gleason 
score 
mean 
Gleason  
score range 
previous 
neg 
biopsies 
cancer  
status 
           
Saito K. 2008 20 
(testpop. 
10) 
67 (median) 51-77     no diagnosed 
           
Shukla-Dave A. 2007 50 
(testpop. 
26) 
60 (median) 44-69 5.4 (median) 0.6 to 24.1 6 (median) 6 to 9 no diagnosed 
           
Testa C. 2007 50 64 51-75 13.9 2.5 to 70   no  diagnosed 
           
Fütterer J. J.  2007 32 61 51-68 7.8 3.2 to 19.4 6  5 to 8 no  diagnosed 
           
Shukla-Dave A.  2007 220   maximum < 20   no one > 6 no diagnosed 
           
Goeb K. 2007 46 65.1 49-77 11.24  6.5 3 to 9 no diagnosed 
           
Reinsberg S. 2007 42 69.3 60-78 10.2(median) 0.45 to 45  6 to 8 no diagnosed 
           
Fütterer J. J.  2006 34 60 50-69 8 3.2 to 23.6 6  5 to 8 no  diagnosed 
           
Shi H. 2006 125 (32 
with 
cancer) 
72.6 58-87  7.2 to 200   no  diagnosed 
           
Jung J.A. 2004 37 56 44-69 5.9 2.2 to 17.2 6.6 5 to 8 no diagnosed 
           
Hasumi M. 2003 21 70 (median) 52-82 51 3.5 to 817  no one > 7 no  diagnosed 
           
Swanson M.G. 2003 26 56 44-70 6.5 0.8 to 15 6.5 5 to 8 no diagnosed 
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Mueller-Lisse U.G. 2001 48 60.2    6.5 5 to 10 no diagnosed 
           
Wefer A. E.  2000 116 58 46-77   6.1 4 to 8 no diagnosed 
           
Scheidler M. D. 1999 89 60.2  8.2  5.3 4 to 10 no diagnosed 
           
Kaji Y. 1998 49 63.2 49-77     no diagnosed 
           
Chen M. 2008 42 63 45-82 11.9 (cancer neg)
52.5 (cancer pos) 
4.7 to 38 
7.4 to 147 
 3 to 8 (>=) no suspected 
           
Cirillo S. 2008 54 65.4 (median) (+/-) 6.5 10.8 (+/-) 7.5 6 (median) 4 to 8 yes suspected 
           
Bhatia C. 2007 21 61.4 50-77 13.1 4.3 to 46.6 6 no range yes suspected 
           
Casciani E. 2007 79 68.1  9.54 4.5 to 40.4   no suspected 
           
Chrzan R. 2006 20 61.9 50-72 10.91 2.9 to 
23.58 
6.18 4 to 9 no suspected 
           
Manenti G. 2006 39 68.5 55-82 24.15 0.3 to 44   no suspected 
           
Kumar V.  2006 33 69.4 (PSA 
>20) 
61.4 (PSA 4-
20) 
 66.4 (PSA >20) 
9.9 (PSA 4-20) 
  2 to 10 (PSA > 20)
2 to 8 (PSA 4-20) 
no suspected 
Costouros N.  2006 45 63 48-80 10.6 5.2 to 24.1 7 (median) 5 to 8 yes suspected 
           
Ansellem-Onazano 
D. 
2005 42 62.3 54-74 12 3.87 to 35 6.6 5 to 9 yes suspected 
           
Squillaci E.  2005 65 68.5 55-82 24.15 4.3 to 44   no suspected 
           
Wetter A. 2005 103 64 46-77 8.6    no suspected 
           
Prando A. 2005 42 63.3 45-75 6.8 4.1 to 15.3   yes suspected 
           
Casciani E.  2004 97      5 to 9 no suspected 
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Yuen J.S.P. 2004 24 64.5 58-69 8.2 (cancer neg) 
20.4 (cancer pos) 
4 to 40   yes suspected 
           
Portalez D.  2004 54 62.9 50-72 10.7 0.95 to 
27.3 
  yes suspected 
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Table 1 Technical characteristics 
 
Author Year MRI    MRSI   Additional techniques 
  model 
field 
strengh
(Tesla) 
weight-
ing coil 
water & lipid 
suppression 
imaging 
development
techique 
voxel 
size  
          
          
Saito K. 2008 Signa, LX Horizon 
Echospeed, GE 
Medical Systems 
1.5 T1+T2 body coil and 
endorectal coil 
PROSE PRESS not 
described 
 
Chen M. 2008 Magnetom Espree, Siemens 1.5 T1+T2 body coil and spine 
coil 
frequency-selective 
refocusing technique 
3D PRESS 
CSI 
STEAM 
1.5 diffusion weighted 
MRI 
Cirillo S. 2008 Signa, GE Medical Systems 1.5 T1+T2 pelvic phased array 
coil 
balloon-covered 
endorectal coil 
selective spatial and 
frequency  
suppression pulses 
PRESS 0.34  
Bhatia C. 2007 CV/i&NV/i, GE Medical 
Systems 
1.5 T1+T2 body coil and pelvic 
phased array 
coil 
balloon covered 
endorectal coil 
done, not described in 
detail 
not described 0.24-0.34  
Shukla-Dave A. 2007 GE Medical Systems 1.5 T1+T2 pelvic phased array 
coil 
endorectal coil 
spectral-spatial pulses 
+ outer 
voxel suppression 
pulses 
PRESS 0.33  
Testa C. 2007 Signa, GE Medical Systems 1.5 T1+T2 body coil 
endorectal coil 
combined with 
pelvic phased array 
coil 
PROSE PRESS 0.34 (PET / CT) 
Shukla-Dave A.  2007 Signa Horizon scanner, GE  1.5 T1+T2 pelvic-phased array 
coil 
expandable 
endorectal coil 
BASING technique PRESS 0.12  
Casciani E. 2007 Signa, GE Medical Systems 1.5 T1+T2 pelvic phased array 
coil 
endorectal coil 
selective spectral 180°  
refocusing pulses 
3D PRESS 
CSI 
0.24-0.70  
Goeb K. 2007 Siemens Medical Systems 1.5 T1+T2 phased array coil 
endorectal coil 
outer volume 
supression 
3D PRESS 
CSI 
0.125-
0.325 
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Reinsberg S. 2007 Intera Philips Medical 
Systems 
1.5 T1+T2 endorectal coil with 
balloon  
BASING technique PRESS CSI 1.15 diffusion weighted 
MRI 
Fütterer J. J.  2007 Magnetom Sonata 
Siemens Medical Systems 
1.5 T1+T2 pelvic phased array 
coil 
endorectal coil 
BASING technique PRESS 0.22  
Manenti G. 2006 Philips Gyroscan Intera 1.5 T1+T2 body coil and 
surface coil near 
the  
pelvis 
BASING technique double spin 
echo 
PRESS 
0.24  
Kumar V.  2006 Sonata / Avanto Siemens 1.5 T1+T2 pelvic phased array 
coil 
endorectal surface 
coil 
six outer volume 
saturation 
bands and frequence 
selective suppression 
3D PRESS 0.125-
0.198 
diffusion weighted 
MRI 
Costouros N.  2006 Signa, GE Medical Systems 1.5 T1+T2 body coil and pelvic 
phased array coil 
expandable 
endorectal coil 
spectral-spatial pulses 
for the 
two 180° excitation 
pulses and outer voxel 
saturation 
double spin 
echo 
PRESS 
0.24-0.34  
Chrzan R. 2006 Signa Excite, GE Medical 
Systems 
1.5 T1+T2 endorectal coil PROSE PRESS not 
described 
 
Shi H. 2006 Siemens Sonata Medical 
Systems 
1.5 T1+T2 not translated not translated not translated not 
translated 
diffusion weighted 
and 
contrast enhanced 
MRI 
Fütterer J. J.  2006 Sonata Siemens Medical 
Systems 
1.5 T1+T2 pelvic phased array 
coil 
endorectal coil 
BASING technique PRESS 0.22 dynamic contrast 
enhanced MR  
Ansellem-
Onazano D. 
2005 Signa, GE Medical Systems 1.5 T1+T2 torso phased array 
coil 
expandable 
endorectale coil 
not described 3D PRESS 
CSI 
0.32  
Squillaci E.  2005 Philips Gyroscan Intera 1.5 T1+T2 body coil and 
surface coil placed 
on 
pubic region 
BASING technique PRESS 0.24 dynamic contrast 
enhanced MR  
Wetter A. 2005 Magnetom Sonata 
Siemens Medical Systems 
1.5 T1+T2 combined pelvic 
phased array coil 
endorectal coil 
BASING technique PRESS 0.45  
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Prando A. 2005 Singa, GE Medical Systems 1.5 T1+T2 body coil and pelvic 
phased array 
coil 
balloon covered 
endorectal coil 
spectral-spatial pulses 
capable of volume 
selection and frequency 
selection 
PRESS 0.34  
Portalez D.  2004 Gyroscan Intera Philips 1.5 T1+T2 endorectal coil   not described not described not 
described 
contrast enhanced 
MRI 
Yuen J.S.P. 2004 Signa Tesla LX Scanner, GE 1.5 T1+T2 phased array torso 
surface coil 
endorectal coil 
not described 3D PRESS 
CSI 
0.328  
Casciani E.  2004 Signa Excite, GE  1.5 T1+T2 phased array coil 
placed on the pelvis 
endorectal coil 
selective spectral 180°  
refocusing pulses 
3D PRESS 
CSI 
not 
described 
 
Jung J.A. 2004 Signa, GE Medical Systems 1.5 T1+T2 body coil and pelvic 
phased array coil 
expandable 
endorectal coil 
BASING technique 3D double 
spin echo 
PRESS 
0.24-0.34  
Hasumi M. 2003 Signa Horizon LX, GE 1.5 T1+T2 endorectal surface 
coil 
not described PRESS 0.59  
Swanson M.G. 2003 Signa, GE Medical Systems 1.5 T1+T2 body coil 
endorectal / pelvic 
phased array coil 
BASING technique 3D double 
spin echo 
PRESS 
0.24-0.34  
Mueller-Lisse U.G. 2001 Signa, GE Medical Systems 1.5 T1+T2 pelvic phased arry 
coil 
endorectal coil 
BASING technique PRESS 0.24  
Wefer A. E.  2000 Signa, GE Medical Systems 1.5 T1+T2 pelvic phased array 
coil 
balloon covered 
endorectal coil 
BASING technique PRESS 
STEAM 
0.25-0.54  
Scheidler M. D. 1999 Signa, GE Medical Systems 1.5 T1+T2 pelvic phased array 
coil 
endorectal coil 
BASING technique PRESS 0.24-0.70  
Kaji Y. 1998 Signa, GE Medical Systems 1.5 T1+T2 body coil and pelvic 
phased array 
coil 
endorectal coil 
BASING technique PRESS 0.24  
 
BASING band selective inversion with gradient dephasing 
PRESS point resolved spectroscopic sequence  
CSI chemical shift imaging  
STEAM stimulated echo acquisition mode  
PROSE prostate spectroscopy and imaging examination, water and lipid suppressing PRESS technique 
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Table 1: Study quality characteristics 
           
Author Year Study attributes   Index test           Reference test 
    study design 
data 
collection 
index test 
descprition blinding 
cutt off 
value 
and level 
region of  
investigation 
single 
pathologic 
correlative 
exclusion due
to poor 
imaging 
quality 
 
  
           
Saito K. 2008 cohort not 
mentioned 
sufficient not described prespecified 
high 
peripheral  
zone 
12th part of 
prostate 
0% prostatectomy 
specimen 
           
Chen M. 2008 cohort retrospective sufficient yes prespecified 
high 
whole 
prostate 
sextant 0% biopsy (8 cores) 
           
Cirillo S. 2008 cohort prospective sufficient not described prespecified 
high 
peripheral  
zone 
patient 0% biopsy (10 cores) 
           
Bhatia C. 2007 cohort prospective sufficient not described prespecified 
high 
whole 
prostate 
patient 0% biopsy (12 cores) 
           
Shukla-Dave A. 2007 cohort retrospective sufficient not described prespecified 
high 
peripheral  
zone 
voxel 32% prostatectomy 
specimen 
           
Testa C. 2007 cohort retrospective sufficient no prespecified 
moderate 
and high 
whole 
prostate 
sextant 10% prostatectomy 
specimen 
           
Shukla-Dave A.  2007 cohort retrospective sufficient yes prespecified 
moderate 
whole 
prostate 
patient 0% prostatectomy 
specimen 
           
Casciani E. 2007 cross 
sectional 
retrospective sufficient yes prespecified 
moderate 
peripheral  
zone 
patient 11% biopsy + 
prostatectomy 
specimen 
           
Goeb K. 2007 cohort prospective sufficient not described prespecified 
high 
whole 
prostate 
third of 
prostate 
0% prostatectomy 
specimen + 
histology reports 
           
Reinsberg S. 2007 cross 
sectional 
prospective sufficient not described optimized whole 
prostate 
voxel 28% biopsy (at least 6 
cores) 
           
Fütterer J. J.  2007 cohort prospective sufficient no prespecified 
low 
whole 
prostate 
tumor nodule 11% prostatectomy  
specimen 
           
Manenti G. 2006 cohort prospective sufficient no  prespeficied 
moderate 
whole 
prostate 
patient 0% biopsy (10 cores) 
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Kumar V.  2006 case 
control 
not 
mentioned 
sufficient no prespecified 
low 
peripheral  
zone 
patient 0% biopsy (6 cores) 
           
Costouros N.  2006 cohort retrospective sufficient yes prespecified 
moderate 
peripheral  
zone 
half of 
prostate 
0% biopsy (6 cores) 
           
Chrzan R. 2006 cohort prospective not described not described prespecified 
high 
whole 
prostate 
patient 0% biopsy (numbers of  
cores undeclarated 
           
Shi H. 2006 case 
control 
not 
mentioned 
sufficient not described prespecified whole 
prostate 
patient 0% biopsy + 
prostatectomy 
specimen 
           
Fütterer J. J.  2006 cohort prospective sufficient yes prespecified 
low 
whole 
prostate 
14th part of 
prostate 
18% prostatectomy 
specimen 
           
Ansellem-Onazano D. 2005 cohort prospective sufficient no prespecified 
moderate 
and high 
whole 
prostate 
patient 0% biopsy (12 cores) 
           
Squillaci E.  2005 cohort prospective sufficient no prespecified 
moderate 
whole 
prostate 
patient 0% biopsy (10 cores) 
           
Wetter A. 2005 cohort not 
mentioned 
sufficient not described prespecified 
moderate 
and high 
whole 
prostate 
patient 28% biopsy (numbers of  
cores undeclarated 
           
Prando A. 2005 cohort not 
mentioned 
sufficient not described prespecified 
high 
peripheral  
zone 
patient 0% biopsy (12 cores) 
           
Portalez D.  2004 cohort prospective sufficient not described prespecified 
moderate 
whole 
prostate 
patient 21% biopsy (12 cores) 
           
Yuen J.S.P. 2004 cohort prospective sufficient yes prespecified 
high 
peripheral  
zone 
patient 0% biopsy (10-14 cores) 
           
Casciani E.  2004 cohort retrospective sufficient yes prespecified 
moderate 
peripheral  
zone 
patient 7% multipe biopsies 
           
Jung J.A. 2004 cross 
sectional 
retrospective sufficient no prespecified 
moderate 
and high 
peripheral  
zone 
voxel 41% of patients
73% of voxels 
prostatectomy 
specimen 
           
Hasumi M. 2003 cohort not 
mentioned 
sufficient not described prespecified 
high 
peripheral  
zone 
half of 
prostate 
0% biopsy (numbers of  
cores undeclarated 
           
Swanson M.G. 2003 cohort not 
mentioned 
sufficient not described prespecified 
moderate 
whole 
prostate 
tumor nodule 2% prostatectomy 
specimen 
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Mueller-Lisse U.G. 2001 cohort not 
mentioned 
sufficient no prespecified 
moderate 
and high 
peripheral  
zone 
sextant 16% prostatectomy 
specimen 
Wefer A. E.  2000 cross 
sectional 
not 
mentioned 
sufficient no prespecified 
moderate 
peripheral  
zone 
sextant 2% of patients 
11% of sextants 
prostatectomy 
specimen 
           
Scheidler M. D. 1999 cross 
sectional 
retrospective sufficient no prespecified 
moderate 
and high 
peripheral  
zone 
sextant 9% of patients 
26% of sextants 
prostatectomy 
specimen 
           
Kaji Y. 1998 cohort retrospective sufficient not described prespecified 
high 
whole 
prostate 
tumor nodule 0% biopsy (4-12 cores) 
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Table 2 true and false positive, true and false negative, Sensitivity and Specificity  
Author Year true  positive 
false  
positive 
false  
negative 
true  
negative Sensitivity Specificity 
        
Included in meta-analysis             
        
Diagnosed cancer - single pathologic correlative subpart of prostate     
Testa C. 2007 44 5 47 44 48 90 
Goeb K. 2007 11 0 17 8 39 100 
Jung J.A. 2004 56 32 25 267 69 89 
Hasumi M. 2003 28 1 3 13 90 91 
Swanson M.G. 2003 17 3 7 26 71 90 
Mueller-Lisse U.G. 2001 111 22 41 68 73 76 
Wefer A. E.  2000 91 16 71 72 56 82 
Scheidler M. D. 1999 80 7 75 72 52 91 
Kaji Y. * 1998 13 3 3 13 81 77 
Kaji Y. ** 1998 36 24 4 42 90 64 
        
Suspected cancer - single pathologic correlative whole prostate / patient     
Cirillo S. 2008 15 6 2 31 88 84 
Bhatia C. 2007 2 3 0 16 100 84 
Casciani E. 2007 41 5 5 19 89 79 
Ansellem-Onazano D. 2005 9 1 6 26 60 96 
Chrzan R. 2006 10 2 1 7 91 78 
Casciani E.  2004 35 3 2 13 95 81 
Yuen J.S.P. 2004 1 0 6 17 14 100 
        
Excluded from meta-analysis             
        
Not combined analysis of MRI and MRSI (MRSI analysis only)       
Saito K. 2008 43 6 28 43 61 88 
Shukla-Dave A. 2007 91 69 124 383 42 85 
Fütterer J. J.  2007 76 43 18 259 81 86 
Fütterer J. J.  2006 78 37 20 249 80 87 
Prando A. 2005 12 4 5 21 71 84 
Wetter A. 2005 5 1 1 13 83 93 
Portalez D.  2004 12 2 3 15 80 88 
        
Combined with diffusion weighted MRI           
Reinsberg S. 2007 33 45 14 227 70 84 
Kumar V.  2006 18 10 0 5 100 33 
        
Combined with diffusion weighted and contrast-enhanced MRI       
Shi H. 2006 13 4 2 24 89 95 
        
Not standard imaging procedure - no use of endorectal coil       
Chen M.  2008 43 8 4 197 84 98 
Manenti G. 2006 14 2 6 17 70 89 
Squillaci E.  2005 24 3 9 29 71 90 
        
Exclusion due to heterogenity within meta-analysis groups       
Shukla-Dave A.  2007 121 48 8 43 93 47 
Costouros N.  2006 9 11 18 42 35 79 
                
* and **: same study, but two different populations: * with and ** without previous hormonal treatment 
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Appendix: Medline (PubMed Interface) search terms and strategy 
 
#1 MRI 
#2 “Magnetic Resonance Imaging” [Mesh] 
#3 “Magnetic Resonance Imaging” 
#4 “Magnetic Resonance Spectroscopy” [Mesh] 
#5 “Magnetic Resonance Spectroscopy” 
#6 “MR Spectroscopy” 
#7 MRS 
#8 “MR Imaging” 
#9 “NMR Tomography” 
#10 “NMR Imaging” 
#11 #4 OR #5 OR #6 OR #7 
#12 #1 OR #2 OR #3 OR #8 OR #9 OR #10 
#13 #11 AND #12 
#14 “Prostatic Neoplasms” [Mesh] 
#15 Prostate carcinoma 
#16 Prostatic Cancer 
#17 Prostate Cancer 
#18 Prostatic Carcinoma 
#19 #14 OR #15 OR #16 OR #17 OR #18 
#20 #13 AND #19  
 
Last search was performed in August 2008. 
 
 
